Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4

M. A. Skinner, A. J. Langlois, C. B. McDanal, J. S. McDougal, D. P. Bolognesi, T. J. Matthews

Research output: Contribution to journalArticle

162 Citations (Scopus)

Abstract

Animals immunized wih the human immunodeficiency virus type 1 gp160 glycoprotein or certain recombinant envelope components develop potent virus-neutralizing activity. This activity is principally due to antibodies directed toward a hypervariable region of gp120 between cysteine residues 302 and 337 and is virus isolate specific. These antisera, as well as two neutralizing monoclonal antibodies directed against the same hypervariable sequence, do not appreciably block gp120 from binding CD4. In contrast, serum samples from infected humans possess high titers of antibodies that block gp120-CD4 binding; these titers approximately correlate with the serum neutralization titers. Our results suggest that there are at least two targets on the envelope glycoprotein for virus neutralization. The target responsible for the broader neutralizing activity of human serum may be a conserved region of gp120 involved in CD4 binding. The antibodies directed at the hypervariable region of the envelope inhibit a different step in virus infection which is subsequent to receptor binding. The extent to which these two different epitopes of gp120 may be involved in protection against human immunodeficiency virus infection is discussed.

Original languageEnglish (US)
Pages (from-to)4195-4200
Number of pages6
JournalJournal of Virology
Volume62
Issue number11
StatePublished - 1988

Fingerprint

blood serum
Neutralizing Antibodies
neutralizing antibodies
neutralization
Virus Diseases
Viruses
viruses
antibodies
Antibodies
glycoproteins
Glycoproteins
Serum
HIV infections
neutralization tests
Human immunodeficiency virus 1
Human Activities
epitopes
Cysteine
cysteine
antiserum

ASJC Scopus subject areas

  • Immunology

Cite this

Skinner, M. A., Langlois, A. J., McDanal, C. B., McDougal, J. S., Bolognesi, D. P., & Matthews, T. J. (1988). Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4. Journal of Virology, 62(11), 4195-4200.

Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4. / Skinner, M. A.; Langlois, A. J.; McDanal, C. B.; McDougal, J. S.; Bolognesi, D. P.; Matthews, T. J.

In: Journal of Virology, Vol. 62, No. 11, 1988, p. 4195-4200.

Research output: Contribution to journalArticle

Skinner, MA, Langlois, AJ, McDanal, CB, McDougal, JS, Bolognesi, DP & Matthews, TJ 1988, 'Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4', Journal of Virology, vol. 62, no. 11, pp. 4195-4200.
Skinner MA, Langlois AJ, McDanal CB, McDougal JS, Bolognesi DP, Matthews TJ. Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4. Journal of Virology. 1988;62(11):4195-4200.
Skinner, M. A. ; Langlois, A. J. ; McDanal, C. B. ; McDougal, J. S. ; Bolognesi, D. P. ; Matthews, T. J. / Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4. In: Journal of Virology. 1988 ; Vol. 62, No. 11. pp. 4195-4200.
@article{8082244f3038499eb72500f533793c4b,
title = "Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4",
abstract = "Animals immunized wih the human immunodeficiency virus type 1 gp160 glycoprotein or certain recombinant envelope components develop potent virus-neutralizing activity. This activity is principally due to antibodies directed toward a hypervariable region of gp120 between cysteine residues 302 and 337 and is virus isolate specific. These antisera, as well as two neutralizing monoclonal antibodies directed against the same hypervariable sequence, do not appreciably block gp120 from binding CD4. In contrast, serum samples from infected humans possess high titers of antibodies that block gp120-CD4 binding; these titers approximately correlate with the serum neutralization titers. Our results suggest that there are at least two targets on the envelope glycoprotein for virus neutralization. The target responsible for the broader neutralizing activity of human serum may be a conserved region of gp120 involved in CD4 binding. The antibodies directed at the hypervariable region of the envelope inhibit a different step in virus infection which is subsequent to receptor binding. The extent to which these two different epitopes of gp120 may be involved in protection against human immunodeficiency virus infection is discussed.",
author = "Skinner, {M. A.} and Langlois, {A. J.} and McDanal, {C. B.} and McDougal, {J. S.} and Bolognesi, {D. P.} and Matthews, {T. J.}",
year = "1988",
language = "English (US)",
volume = "62",
pages = "4195--4200",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "11",

}

TY - JOUR

T1 - Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4

AU - Skinner, M. A.

AU - Langlois, A. J.

AU - McDanal, C. B.

AU - McDougal, J. S.

AU - Bolognesi, D. P.

AU - Matthews, T. J.

PY - 1988

Y1 - 1988

N2 - Animals immunized wih the human immunodeficiency virus type 1 gp160 glycoprotein or certain recombinant envelope components develop potent virus-neutralizing activity. This activity is principally due to antibodies directed toward a hypervariable region of gp120 between cysteine residues 302 and 337 and is virus isolate specific. These antisera, as well as two neutralizing monoclonal antibodies directed against the same hypervariable sequence, do not appreciably block gp120 from binding CD4. In contrast, serum samples from infected humans possess high titers of antibodies that block gp120-CD4 binding; these titers approximately correlate with the serum neutralization titers. Our results suggest that there are at least two targets on the envelope glycoprotein for virus neutralization. The target responsible for the broader neutralizing activity of human serum may be a conserved region of gp120 involved in CD4 binding. The antibodies directed at the hypervariable region of the envelope inhibit a different step in virus infection which is subsequent to receptor binding. The extent to which these two different epitopes of gp120 may be involved in protection against human immunodeficiency virus infection is discussed.

AB - Animals immunized wih the human immunodeficiency virus type 1 gp160 glycoprotein or certain recombinant envelope components develop potent virus-neutralizing activity. This activity is principally due to antibodies directed toward a hypervariable region of gp120 between cysteine residues 302 and 337 and is virus isolate specific. These antisera, as well as two neutralizing monoclonal antibodies directed against the same hypervariable sequence, do not appreciably block gp120 from binding CD4. In contrast, serum samples from infected humans possess high titers of antibodies that block gp120-CD4 binding; these titers approximately correlate with the serum neutralization titers. Our results suggest that there are at least two targets on the envelope glycoprotein for virus neutralization. The target responsible for the broader neutralizing activity of human serum may be a conserved region of gp120 involved in CD4 binding. The antibodies directed at the hypervariable region of the envelope inhibit a different step in virus infection which is subsequent to receptor binding. The extent to which these two different epitopes of gp120 may be involved in protection against human immunodeficiency virus infection is discussed.

UR - http://www.scopus.com/inward/record.url?scp=0023687226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023687226&partnerID=8YFLogxK

M3 - Article

VL - 62

SP - 4195

EP - 4200

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 11

ER -